DT07 Rec'd PCT/PTO 0 8 SEP 2004

EV485023544US Express Mail Label Number

SEPTEMBER 8, 2004
Date of Deposit

| | | - |
|---|---|---|
| Form PTO-1390-MOD U. S. (REV 10-96) | Department of Commerce Patent and Trademark Office | ATTORNEY'S DOCKET NUMBER PC/4-32388A |
| TRANSMITTAL LETTER TO THE UNITED STATES | | U.S. APPLICATION NO. (If known, see 37 CFR 1.5 |
| DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | |
| INTERNATIONAL APPLICATION NO. PCT/EP03/02365 | INTERNATIONAL FILING DATE 7 March 2004 (07.03.03) | PRIORITY DATE CLAIMED 8 March 2002 (08.03.02) |
| TITLE OF INVENTION MATRIX METALLOPROTEINASE INHIBITO FOR THE TREATMENT OF CANCER | RS IN COMBINATION WITH HYPC | OTHERMIA AND/OR RADIOTHERAP |
| APPLICANT(S) FOR DO/EO/US NAKAJIMA ET AL. | | |
| Applicant herewith submits to the United States De | esignated/Elected Office (DO/EO/US) the | ne following items and other information: |
| This is a FIRST submission of ite This is a SECOND or SUBSEQUE This express request to begin nat than delay examination until the e PCT Articles 22 and 39(1). | ENT submission of items concertional examination procedures (3 expiration of the applicable time I | rning a filing under 35 U.S.C. 371. 5 U.S.C. 371(f)) at any time rathe imit set in 35 U.S.C. 371(b) and |
| 4. A proper Demand for International earliest claimed priority date. 5. A copy of the International Application a. is transmitted herewith (rection b). has been transmitted by the c. is not required, as the application and the second properties. | ation as filed (35 U.S.C. 371(c)(2 quired only if not transmitted by tl e International Bureau. (See Fo | 2)) he International Bureau). rm PCT/IB/308) |
| 6. A translation of the International A7. Amendments to the claims of the U.S.C.371(c)(3)). | Application into English (35 U.S.0 | C. 371(c)(2)). PCT Article 19 (35 |
| b. have been transmitted by t | he International Bureau. ever, the time limit for making suc vill not be made. to the claims under PCT Article over of Attorney (original or copy) | ch amendments has NOT expired 19 (35 U.S.C. 371 (c)(3)). (35 U.S.C. 371(c)(4)). |
| Items 11. to 16. below concern docum | ent(s) or information included | |
| 11. An Information Disclosure Statem | nent under 37 CFR 1.97 and 1.98 | 3. |
| 12. An assignment document for reco | ording. A separate cover sheet in | n compliance with 37 CFR 3.28 |
| 13. ☐ A FIRST preliminary amendment.☐ A SECOND or SUBSEQUENT preliminary amendment. | | |
| 14. A substitute specification. | | |
| 15. A change of power of attorney an | d/or address letter. | |

16. Other items or information: Application Data Sheet, Unexecuted Declaration and Post Card.

D109 Rec'o PCT/PTO 08 SEP 200 U.S. APPLICATION NO. (if known, see 37 CFR 1.5 PCT/EP03/02365 Not Yet Assigned PC/4-32388A 17. The following fees are submitted: CALCULATIONS PTO USE ONLY BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)): \$920 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$730 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... \$770 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$1,080 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100 920 **ENTER APPROPRIATE BASIC FEE AMOUNT =** Surcharge of \$130 for furnishing the oath of declaration later than 20 \$ months from the earliest claimed priority date (37 CFR 1.492(e)). **CLAIMS** NUMBER FILED RATE NUMBER EXTRA Total claims 9 - 20 = 0 \$ 18 0 Independent claims 6 - 3 = 3 258 86 MULTIPLE DEPENDENT CLAIM(S) (if applicable) 290 \$ 1178 TOTAL OF ABOVE CALCULATIONS \$ Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). 1178 SUBTOTAL = Processing fee of \$130 for furnishing the English translation later than 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). 1178 \$ **TOTAL NATIONAL FEE =** Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property 1178 TOTAL FEES ENCLOSED = Amount to be: refunded charged a. 🔲 A check in the amount of \$ to cover the above fees is enclosed. b. 🛛 Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1178 to cover the above fees. A duplicate copy of this form is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to c. 🛛 Deposit Account No. 19-0134 in the name of Novartis.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Customer No. 001095, which is currently:

Send all correspondence to the address associated with

(b)) must be filed and granted to restore the application to pending status.

Edward J. Wildsz J Attorney for Applicants Reg. No. 52,370 (862) 778-7960